Among the most active adjuvant chemotherapy regimens, the docetaxel-based combinations of docetaxel, doxorubicin, and cyclophosphamide (TAC), 6– 8 docetaxel with cyclophosphamide, 9, 10 sequential anthracycline (eg, FEC [5-fluorouracil, epirubicin, and cyclophosphamide]) followed by docetaxel monotherapy, 11– 14 and docetaxel, carboplatin, and trastuzumab 15 are most commonly used.
Anthracyclines are one of the most active agents in primary adjuvant and palliative treatment of breast cancer (Kroger et al, 1999).
Major strengths of this study include a large sample size (n >5,600), precise BMI information at baseline, and a standardized CT treatment based on the most active drugs in the adjuvant setting available at that time (anthracyclines and taxanes).
In conclusion, on the basis of these results, hormone negative or refractory metastatic breast cancer patients should be treated with first-line chemotherapy, including the most active agents, irrespective of prior adjuvant treatment.
When it was decided to administer adjuvant chemotherapy, the most active regimens, anthracycline-based, were selected.
Anthracyclines are among the most active agents in the treatment of metastatic and adjuvant breast cancer (Fossati et al, 1998; EBCTCG, 2004).
The taxanes are among the most active cytotoxic agents in oncology and are widely used in adjuvant and advanced treatment settings in multiple tumor types.
Taxanes are one of the most active agents against breast cancer and are routinely used in metastatic, adjuvant, and neoadjuvant settings.
The optimal anti-HER2 adjuvant treatment will be addressed below Anthracyclines are amongst the most active chemotherapeutic agents for the treatment of breast cancer.
However, to prove its complete adjuvant potential, further study with long-term trials and on identification of the most active compound of garlic is necessary.
Then, chalcone-spermine conjugates 7d and 8d were shown to be the most active of the series and could be considered as promising compounds for colon and prostatic cancer adjuvant therapy.
